Carisma Therapeutics, Inc. (NASDAQ:CARM – Get Free Report) has been assigned an average rating of “Buy” from the five brokerages that are currently covering the firm, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a buy rating. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $10.00.
CARM has been the subject of a number of research analyst reports. Capital One Financial initiated coverage on shares of Carisma Therapeutics in a report on Tuesday. They issued an “overweight” rating and a $10.00 price target for the company. Evercore ISI initiated coverage on shares of Carisma Therapeutics in a report on Thursday, July 6th. They issued an “outperform” rating and a $12.00 price target for the company. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $11.00 price target on shares of Carisma Therapeutics in a report on Wednesday, September 6th.
Get Our Latest Stock Report on CARM
Carisma Therapeutics Price Performance
Carisma Therapeutics (NASDAQ:CARM – Get Free Report) last announced its earnings results on Thursday, August 10th. The company reported ($0.49) earnings per share for the quarter, beating the consensus estimate of ($0.66) by $0.17. The firm had revenue of $3.56 million during the quarter. Sell-side analysts forecast that Carisma Therapeutics will post -2.59 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several institutional investors have recently made changes to their positions in the business. Barclays PLC purchased a new position in shares of Carisma Therapeutics during the second quarter worth $47,000. California State Teachers Retirement System acquired a new stake in Carisma Therapeutics during the second quarter valued at $78,000. Nuveen Asset Management LLC acquired a new stake in Carisma Therapeutics during the second quarter valued at $875,000. Wells Fargo & Company MN grew its position in Carisma Therapeutics by 1,957.9% during the second quarter. Wells Fargo & Company MN now owns 10,598 shares of the company’s stock valued at $93,000 after buying an additional 10,083 shares during the period. Finally, Goldman Sachs Group Inc. acquired a new stake in Carisma Therapeutics during the second quarter valued at $243,000. Hedge funds and other institutional investors own 32.22% of the company’s stock.
Carisma Therapeutics Company Profile
Carisma Therapeutics, Inc, a biopharmaceutical company, develops chimeric antigen receptors (CAR) macrophages for the treatment of solid tumors. Its solutions are used to play a crucial role in the innate and adaptive immune response, and technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human diseases.
Featured Stories
- Five stocks we like better than Carisma Therapeutics
- How to Evaluate a Stock Before Buying
- Huawei Has Entered The Chips Race, Markets Still Prefer These
- What is the Euro STOXX 50 Index?
- Restaurant Stocks Go on Sale…Which Are Really on the Value Menu?
- Investing in Construction Stocks
- 5 Reasons to Buy and Hold Exxon Mobil For 2024
Receive News & Ratings for Carisma Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Carisma Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
